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tbstract Programmed cell death, or apoptosis, has in the past 
few years undoubtedly become one of the most intensively 
investigated biological processes. However, fundamental ques- 
lions concerning the molecular and biochemical mechanisms 
remain to be elucidated. The central question concerns the 
biochemical steps shared by the numerous death induction 
pathways elicited by different stimuli. Heterogeneous death 
signals precede a common effector phase during which cells pass 
a threshold of'no return' and are engaged in a degradation phase 
where they acquire the typical onset of late apoptosis. Alterations 
in mitochondrial permeability transition linked to membrane 
potential disruption precede nuclear and plasma membrane 
changes. In vitro induction of permeability transition in isolated 
mitochondria provokes the release of a protein factor capable of 
inducing nuclear chromatin condensation and fragmentation. 
Yhis permeability transition is regulated by multiple endogenous 
effectors, including members of the bcl-2 gene family. Inhibition 
of these effects prevents apoptosis. 
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I. Introduction 
Apoptosis, or programmed cell death (PCD), is a naturally 
, ,ccurring process of cell 'suicide' that plays a crucial role in 
:ae development and maintenance of metazoans by eliminat- 
lg superfluous or unwanted cells [1,2]. Disturbed apoptosis 
~lays a major role in diseases uch as cancer, acquired im- 
~aune deficiency syndrome, autoimmune disease, and neuro- 
~:egeneration. The biochemical basis for apoptotic ell death is 
onstitutively present in virtually all mammalian cells and can 
l~e activated by a wide variety of extra- and intra-cellular 
signals [3]. The induction phase of PCD or apoptosis is char- 
~:cterized by an extreme heterogeneity of potential PCD-trig- 
cering signal transduction pathways. 
Although apoptosis research as exponentially grown the 
I tst few years, fundamental questions concerning the molecu- 
1 tr and biochemical mechanisms of apoptosis remain to be 
elucidated. A great deal of effort has been dedicated to bio- 
hemical studies of its initiation and regulation, in order to 
~ evelop new methods of enhancement or inhibition of the 
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.-tbbreviations: AIF, apoptosis inducing factor; A~m, mitochondrial 
membrane potential; ICE, interleukin-l[3 converting enzyme; PCD, 
programmed cell death; PT, permeability transition pore; ROS, 
r,~active oxygen species: TNF, tumor necrosis factor 
process in disease, with considerable benefit for patients [4]. 
In contrast, relatively little is known about the mechanism 
involved in the execution of apoptosis [5]. The central ques- 
tion concerns the hypothetical biochemical steps shared by the 
numerous death induction pathways elicited by different sti- 
muli. Structural and functional similarities between mamma- 
lian proteins that regulate PCD and those encoded by cell 
death genes in the nematode worm Caenorhabditis elegans 
indicate that the molecular mechanism of PCD has been evo- 
lutionarily conserved. Moreover, recent findings indicate that 
a similar process of socially advantageous regulation of cell 
survival also operates in single-cell eukaryotes [6]. 
The hypothesis of a central executioner of the PCD was 
reinforced by the discovery of the proto-oncogene bcl-2 which 
is structurally and functionally related to the product of the 
Caenorhabditis elegans cell death-protecting gene ced-9 and its 
protective action in a variety of cell death systems [7,8]. Ced-9 
is an element of a polycistronic locus that also contains the 
gene cyt-1, which encodes a protein similar to the cytochrome 
b56~ of complex II of the mitochondrial respiratory chain 
[8]. 
Bcl-2 is the product of the bcl-2 apoptosis-inhibitory proto- 
oncogene. The human bcl-2 gene can function in C. elegans to 
suppress PCD [2,8]. In a number of systems Bcl-2 fails to 
protect against cell death. Bcl-2 is only one, however, of a 
numerous family of recently discovered imerizing proteins 
(Bcl-XE, Mcl-1, Bfl-1, A1 etc.) which influence cell death [9]. 
Some, like Bax (or Bad, Bak) heterodimerize with Bcl-2 and 
others to abrogate its inhibition of apoptosis. Susceptibility o
apoptosis may therefore be determined by multiple competing 
dimerizations in which Bax and its relatives may be common 
partners [10]. Some family members, like Bcl-2, suppress or 
delay PCD, while others promote death, although the mech- 
anisms are unknown. The failure of Bcl-2 to protect against 
apoptosis can be explained by postulating that there are addi- 
tional parallel death pathways that are related to, yet distinct 
from Bcl-2. It also is reasonable to suppose that the molecular 
targets of the Bcl-2 family members are part of a pathway 
leading to apoptotic death which has been conserved through- 
out evolution. 
2. Reactive oxygen species (ROS), Bcl-2 and programmed cell 
death 
Bcl-2 was initially thought to be located in the mitochon- 
drial membrane [11], suggesting that it might directly affect 
primarily mitochondrial function. It has since been found by 
immunolocalization to be in the outer mitochondrial mem- 
branes but also in the membranes of the endoplasmic reticu- 
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Table 1 
Models in which the AWm reduction precedes apoptosis 
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Cells Inducer Reference 
Neurons 
Fibroblasts 
Pre-B cells (WEHI-231) 
T lymphocytes and T cell hybdridomas 
Thymocytes 
Myelomonocytic cells (U937) 
Deprivation of nerve growth factor [81] 
p53 [55] 
Anti-IgM [57] 
Glucocorticoids [57] 
Superantigen [82] 
T cell receptor crosslinking [69] 
Ceramide 
HIV infection 
Glucocorticoid (dexamethasone) [56] 
Self-antigen (transgenic mice) [58] 
Irradiation [69] 
Etoposide 
TNF4x [57,83,84] 
Cycloheximide 
lum and the nuclear envelope [12,13]. At the mitochondrial 
level, Bcl-2 has a patchy distribution linked to the contact 
sites between the outer and the inner membranes [14]. The 
role of mitochondria nd the importance of the C-terminal 
membrane anchor of Bcl-2 in Bax-induced growth arrest 
and mortality has been recently demonstrated in Saccharo- 
myces cerevisiae [15]. Importantly, Bax kills only yeast cells 
which have functional respiring mitochondria. 
Recent models proposed that Bcl-2 has antioxidant proper- 
ties and inhibits PCD by suppressing the formation or effects 
of ROS [16,17]. This fits well with the location of Bcl-2 in 
organelles known to participate in redox reactions and the 
formation of ROS [18]. Bcl-2 may thus function to protect 
cells against cytoplasmic oxidants involved in mediating apop- 
totic cell death and/or from ROS generated as normal by- 
products of the normal mitochondrial reactions during ATP 
synthesis. 
Aerobic cells are endowed with extensive antioxidant de- 
fence mechanisms to counteract he damaging effects of 
ROS. Under a continual 'oxidative siege' their survival de- 
pends on the balance between ROS production and antioxi- 
dant activity (for review, see [19]). ROS, being highly reactive 
and generally non-specific, are unlikely to mediate the highly 
co-ordinated and controlled changes that occur in PCD. 
Nevertheless, ROS seemed to be involved in some PCD mod- 
els [18]: (i) the addition of ROS or the depletion of endoge- 
nous antioxidants can induce PCD; (ii) PCD can sometimes 
be inhibited by endogenous or exogenous antioxidants [18]; 
(iii) PCD is associated with increases in cellular ROS levels 
[16]. Particularly in TNF-induced apoptosis associated with 
mitochondrial reactive oxygen intermediate production [20]. 
It is unknown whether the production of ROS is essential 
to the progression of PCD. In cells cultured in near anaerobic 
conditions, ROS are unlikely to be produced, although the 
cells can still undergo PCD [21,22]. Hypoxia itself can induce 
PCD and Bcl-2 and BcI-XL can inhibit cell death [23]. These 
findings demonstrate hat Bcl-2 and BcI-XL can inhibit PCD 
in the absence of ROS and that whatever antioxidant proper- 
ties Bcl-2 might have, they are not necessary for Bcl-2 to 
inhibit PCD. 
Other evidence supports the fact the ROS are not required 
for the execution of the cell death program: (i) although some 
antioxidants can inhibit or delay PCD in some systems [24- 
27], they fail to do so in all systems, at least not in PCD 
induced by Fas/APO-1 [28,29] or staurosporine [28]; (ii) anti- 
oxidants and radical scavengers have other activities that 
might exert side effects on molecules required for PCD. 
Many antioxidants are reducing agents and, as such, might 
modify sulfhydryl groups of proteins and alter their functions. 
They also have indirect effects on cellular biochemistry, for 
example, the Cu + chelator 1,10-phenanthroline (OPT) can 
inhibit PCD in thymocytes, suggesting ROS involvement 
[25]. OPT can also inhibit ICE in vitro by preventing the 
metal-catalysed oxidation of an essential thiol suggesting 
that it might inhibit PCD by interaction with an ICE-family 
protease. 
Although ROS do not seem to be required in the execution 
phase of PCD, they can be involved in the activation phase, as 
intracellular signaling molecules [30]. It is necessary to distin- 
guish ROS molecules involved in such signaling pathways 
from those that mediate general cellular damage. It seems 
unlikely that hydroxyl radicals, which are reactive but lack 
of biological specificity, can be specific signalling intermedi- 
ates. However, the hydroxyl radicals might participate to very 
localized processes, within cytoplasmic membranes, during the 
execution phase of PCD. 
3. Proteases as mediators of apoptosis 
In view of these results many investigators have purchased 
apoptotic effectors other than ROS. Cysteine proteases with 
'asp-ase' activity such as the prototypical ICE/ced3 protease 
family, have attracted attention as candidates for common 
apoptotic effector molecules (for review, see [31-33]). The 
emergence of ICE-like proteases detracted from the early in- 
terest in ROS and mitochondria. 
Intracellular proteases might play a critical role in the in- 
itiation of apoptosis: (i) specific and reproducible proteolytic 
cleavage has been identified in apoptosis [34-39]; (ii) certain 
protease inhibitors have been shown to inhibit apoptosis 
[35,40,41]; (iii) some viral proteins capable of inhibiting apop- 
tosis are protease inhibitors [42,43]; (iv) gene knockout ex- 
periments have demonstrated an essential role for a specific 
protease in some physiologic models of apoptosis [44,45]. 
Inhibitors of ICE family proteases are capable of blocking 
PCD triggered by diverse signals, both in vivo and in vitro 
(for a review, see [32]). Among the numerous ICE-like pro- 
tease inhibitors, Z.VAD is a broad-spectrum antagonist of 
numerous proteases that inhibits apoptosis in mammalian 
and insects cells [46,47]. These data suggest hat the ICE pro- 
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Mitochondrial PT 
• After in vitro ca 2+ accumulation, 
mitochondria can undergo 
a sudden permeabil ity increase 
to solutes with molecular mass < 1.5 kDa. 
• As first proposed by Hunter and 
Haworth [*], the permeabil ity changes 
are mediated by the permeabil ity 
transition pore (PT), 
a t ransmembrane channel 
inhibited by cyclosporin A .  
• The PT may coincide 
with the mitochondrial  megachannel, 
inhibited by cyclosporin A and 
which responds to most effectors 
as does the permeabil ity transition. 
. l lm.  i i i i 
How the  PT  funct ion?  
• The mitochondrial  transition 
pore act as a: 
1 - Voltage sensor. 
2 - Thiols sensor. 
3 - Sensor of the oxido-reduction status 
of the pyridine nucleotide pool. 
4 - Matrix pH sensor. 
5 - Sensor of divalents cations 
6 - Sensor of adenine nucleotides. 
J 
Detection of the PT 
• Isolated mitochondria are resuspended 
in a protein-free buffer. 
• PT gives rise to the 
colloidosmotic swelling of mitochondria, 
this large amplitude swelling is followed 
through optical density changes at 540 nm. 
• PT can also be quantif ied using 
radioactive markers (Sucrose, Ca 2+ etc.). 
L • Patch-clamp techniques identify 
|the so-called "mitochondrial  megachannel" 
which is CsA-inhibitable 
and probably identical with the PT 
f PT  and  phys io log ica l  funct ions  
• Periodic reversible pore opening 
in physiological conditions 
allow for the release of calcium 
from mitochondrial  matrix, 
thus being implicated 
in the cellular calcium homeostasis. 
• PT also facilitate the AqJm-diven 
import of proteins 
into the mitochondrial  matrix. 
• It also might be implicated 
in fast answerto perturbat ion 
of the energy status of the cell. 
• Massive PT opening 
culminate in cell death. 
, ,  . . . . . . . . . . .  
tig. 1. Summary of the structure and function of the mitochondrial permeability transition. (*) Hunter and Haworth [79]. All information sum- 
~ ~arized from Bernardi et al. [68], Zoratti et al. [66] and Constantini et al. [80]. 
1,.:ase family plays a central shared functional role in apoptotic 
~eath pathways. Two examples of apoptotic ell death that 
~,re not blocked by inhibitors of ICE-like proteases (AcY- 
\AD-peptide) concern: (1) IL-2 withdrawal-induced cell 
death and DNA fragmentation i murine CTLL-2 cells even 
taough these inhibitors blocked IL-I~ production and (2) Fas- 
mediated apoptosis in other murine cells [48]. The significance 
f the failure of the inhibitors of the ICE-like proteases to 
block cell death is difficult to interpret given our incomplete 
1, nowledge of the specificity of the proteases. It may also well 
be that some cases of PCD are not mediated by ICE-family 
1 c, roteases. 
4. Alterations of mitochondrial functions as early event of 
apoptosis 
Until recently, mitochondria were thought to be morpho- 
logically normal during apoptotic ell death whereas they ap- 
pear swollen in necrotic ells. However, some data indicate a 
breakdown of mitochondrial function during apoptosis. An 
inhibition of oxidative ATP production has been reported to 
be associated with glucocorticoid-induced lymphocyte apop- 
tosis [49] and a decreased mitochondrial dehydrogenase ability 
to cleave tetrazolium salt (MTT) [50] has been reported in 
anti-CD3-induced apoptosis of T-cells [51]. In the case of 
TNFe~-induced apoptosis [52], early disruption of mitochon- 
drial function [53,54] has been described. More recently, an 
early drop of mitochondrial membrane potential (AWm) which 
correlates with an uncoupling of electron transport from ATP 
production, a drop of the rate of mitochondrial translation 
and defect in mitochondrial protein cytoplasmic precursors 
maturation have been observed during the commitment to 
apoptosis of cell conditionally immortalized with SV40 [55]. 
A similar drop of A~m associated with cardiolipin alteration 
10 
Table 2 
Inducers and inhibitors of the mitochondrial PT pore and/or apoptosis 
P.X. Petit et al./FEBS Letters 396 (1996) ~13 
Substances Interaction with Effect on the PT Effect on apoptosis Reference 
Calcium 
Pro-oxidants 
(tert.-butyl- 
hydroperoxide, 
H202) 
Diamide 
Uncoupling 
agents 
(mCICCP) 
Protoporphyrin 
IX (PPIX) 
Atractyloside 
Bongkrekic acid 
(BA) 
Cyclosporin A 
(CsA) 
Ruthenium red 
Monochlorobi- 
mane 
Unknown Induction Induction 
Unknown Induction Induction 
Vicinal thiols (crosslinker) 
Membranes (protonophore) 
Ligand of the peripheral (outer 
mitochondrial membrane) benzo- 
diazepine receptor, a putative 
constituent of the multi-subunit 
PT pore 
Interaction with the external 
domains of the adenine nucleotide 
translocator, another putative 
constituent of the PT pore 
Ligand of the adenine nucleotide 
translocator (matrix side) 
Interaction with the cyclophilin 
isoenzyme of the mitochondrial 
matrix 
Inhibitor of the inner mitochondrial 
membrane calcium uniport 
Thiols (inhibits disulfide bridge for- 
mation between vicinal thiols) 
Induction Induction 
Induction Induction 
Induction Induction 
Induction 
Inhibitor of PT induced by 
atractyloside, oxidants, and 
uncoupling agents, not calcium 
or diamide 
Short-term inhibitor ( < 60 min) 
Inhibitor of PT induced by 
calcium, not pro-oxidants, 
uncoupling agents, or diamide 
Inhibitor of PT induced by 
diamide 
No effect (not membrane- 
permeable) 
Inhibitor of apoptosis induction 
by oxidants, uncoupling agents, 
glucocorticoids, or DNA damage 
No major effect, synergistic 
inhibitory effects with BA 
No effect 
Inhibitor of apoptosis nduced by 
glucocorticoid and DNA damage 
[85] 
[62] 
[63] 
[62] 
[62] 
[62] 
Unpublished 
Unpublished 
~For Ca 2+ and pro-oxidants, for isolated mitochondria, cf. [66,68]. 
is also an early event of dexamethasone-induced thymocyte 
apoptosis [56-58] (Table 1). 
The finding that the Bcl-2 proto-oncogene product can lo- 
cate to the mitochondrial membrane [11] and that its ability to 
suppress apoptosis is reduced in constructs that lack the C- 
terminal transmembrane s gment [16,59] has suggested that 
Bcl-2 acts at the mitochondrial level. Since it has been found 
that Bcl-2 blocks apoptosis in cells that do not contain a 
functional respiratory chain (cells lacking mtDNA) [60], it 
has been concluded that apoptosis itself and the antiapoptotic 
activity of Bcl-2 are not related to mitochondrial respiration. 
These experiments do not exclude that mitochondrial events 
might be involved in apoptosis. Cells devoid of mtDNA have 
been selected for their ability to grow in the presence of ethi- 
dium bromide (which inhibits mtDNA replication). The 
clones are selected for their ability to grow and survive in 
the absence of respiration. These cells generates ATP by gly- 
colysis and maintain a normal AWm, probably by using the 
ADP/ATP translocator to import glycolytic ATP in the mito- 
chondria [61-63]. Thus it remains possible that a mitochon- 
drial function, not directly linked to respiration but possibly 
to the A~m, is involved in apoptosis. Second, a depletion of 
the mitochondrial electron transport abrogates the cytotoxic 
effect of TNFc~ [64]. In the same system, the overexpression f 
Bcl-2 has been shown to increase A~m and this effect could be 
linked to its anti-apoptotic activity since the ionophore niger- 
icin, known to increase A~m, has a similar effect [65]. A new 
interest emerges from recent work [57,58,62] and brings back 
the mitochondria under the apoptosis earchlights, as a crucial 
common step in PCD is the opening of the mitochondrial 
'megachannel' or permeability transition pore (PT). 
5. Modulation of mitochondrial permeability transition decides 
cell fate 
A number of different substances regulate the probability of 
PT pore opening and closing [66]. The heterogeneous catalo- 
gue of PT inducers [67,68] comprises divalent cations, pro- 
oxidants, thiol-crosslinking agents, and more specifically lig- 
ands of proteins thought to be involved in the formation 
of PT pores (adenine nucleotide translocator, peripheral ben- 
zodiazepine receptor). Such substances, which can induce PT 
in isolated mitochondria (Fig. 1), are also highly efficient PT 
inducers in cells. They provoke one of the cardinal feature of 
PT, namely AUdm disruption and by superoxide anion genera- 
tion. In doing so, PT opening induces apoptosis in lymphoid 
cells and cell lines (Table 2). Inhibitors of PT such as bong- 
krekic acid or the monovalent thiol-reactive agent monochlor- 
obimane can inhibit apoptosis induced by glucocorticoids, 
irradiation or topoisomerase inhibition (Table 2). AWm disrup- 
tion and subsequent nuclear apoptosis are strictly co-regu- 
lated, i.e. whenever a cell loses its A~m it will die from apop- 
tosis, and vice versa, whenever a cell is protected against 
apoptosis induction, it will maintain its AUgm. Inhibition of 
thymocyte apoptosis by inhibitors of mRNA synthesis, 
mRNA translation, protease activation, antioxidants or p53 
null mutation prevents the Ahvm disruption that normally fol- 
lows exposure to the pro-apoptotic stimulus [69]. Bcl-2 pre- 
vents the PT-mediated A~m collapse, both in cells and in 
isolated mitochondria [62]. Thus, a proto-oncogene product 
exerts a direct control on mitochondrial PT. In a cell-free 
system, in which purified nuclei are exposed to cytoplasmic 
compounds, mitochondria are necessary to reproduce the fea- 
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Sub,necrotic damages 
(Biochemical and chemical) 
• ROS 
• Changes in 
oxido-reduction 
• ADP/ATP ratio 
Q 
Receptor-mediated apoptosis 
(External and internal receptors) 
Bc l -2 -  
BcI-XL 
® 
? ~ z,VAD,fmk 
® 
z-VAD.fmk 
ROS 
! ig. 2. Hypothetical model of apoptosis regulation. Apoptosis can be induced by biochemical or chemical signals mediated via internal or exter- 
H1 receptors. Signal transduction pathways after apoptotic stimuli are numerous. Reactive oxygen species (ROS), alteration of the cellular re- 
dox potential and/or changes in ADP/ATP ratio involve some but not all of the pathways of apoptosis induction. ICE and ICE/Ced-3 pro- 
t~ases, as well serine proteases appear to intervene in the 'private pathway' of apoptosis. The different signal transduction pathways converge 
i~to a common apoptotic pathway to all cells apoptosis through the induction of mitochondrial permeability transition (MPT). The Bcl-2 pro- 
t,,-oncogene intervenes at the level of MPT induction in response to some but not all MPT inducers. As a consequence of the pore opening, 
mitochondria release a protein (apoptosis inducing factor, AIF) capable of causing nuclear apoptosis in cell-free systems. PT is related to the 
nfitochondrial generation of ROS, as well as a rapid exposure of phosphatidyl serine residues at the outer plasma membrane surface. These 
c langes form a part of the degradation phase of apoptosis. It is probable that the permeability transition is linked to an activation of specific 
proteases, although the exact mechanisms underlaying their action remain unknown. Enhanced ROS generation, depletion in reduced glu- 
t~tthione, increase in cellular calcium and nuclear apoptosis are likely to be independent events not linked in a strict cause-effect relationship 
bJt all belonging to the degradation phase of apoptosis. 1: induction phase: 2: effector phase: 3: degradation phase. 
tares of nuclear apoptosis [70]. Only mitochondria that are 
undergoing PT are pro-apoptotic in this system [62], and in- 
hibition of PT prevents mitochondria from apoptotic cells 
f iom inducing apoptosis in isolated nuclei. 
Other recent data suggest hat a pre-formed > 10 kDa pro- 
t~in is released from mitochondria upon AU/m disruption 
v. hich causes isolated nuclei to undergo chromatin condensa- 
tion and nuclear fragmentation [62,71]. The effects of this 
a~optosis inducing factor (AIF) are blocked by N-benzylox- 
~carbonyl-Val-Ala-Asp.fluoromethylketone (z-VAD.fmk), an 
altagonist of interleukin-ll3 converting enzyme (ICE)-like 
proteases which is also an efficient inhibitor of apoptosis in 
cells. Bcl-2 hyperexpressed in the outer mitochondrial mem- 
brane also impedes the release of A IF  from mitochondria in 
wtro without affecting its formation. Either the presence of 
Bcl-2 in the nuclear membrane nor the Bcl-2 hyperexpression 
protects cells against A IF  [71]. Bcl-2 may thus also prevent 
apoptosis by favoring the retention of an apoptogenic mito- 
chondrial protease. These new results have the advantage of 
giving a link between mitochondria and proteases without 
excluding the possibility that proteases act upstream of the 
PT pore opening in other cell death systems (Fig. 2). 
6. Bcl-Xr+ (Bcl-2) and pore regulation 
The recent crystallization of Bcl-XL [72], a member of the 
Bcl-2 family [73], has revealed a central structure containing 
two c~-helices surrounded by amphiphatic helices. Three func- 
tionally important Bcl-2 proteins homology regions (BH1, 
BH2 and BH3) [74-76] are in close spatial proximity and 
form an hydrophobic cleft which may be the binding site 
for other Bcl-2 family members. 
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The arrangement of the c~-helices in a pore like structure is 
reminiscent of the membrane translocation domain of bacte- 
rial toxins, like diphtheria toxin and colicins [77]. By analogy 
to the diphtheria toxin translation domain [78], Bcl-2 proteins 
may form pores in the membranes where they localized [72]. 
The insertion of Bcl-2 proteins like the bacterial proteins, may 
be regulated by signals dependent on voltage and pH [72]. It 
has also been demonstrated that Bcl-2 inhibits the release of 
the mitochondrial Z.VAD inhibitable protein factor (AIF) 
which is released upon A~m disruption and causes nuclei to 
undergo chromatin condensation and internucleosomal frag- 
mentation [71]. These data suggest hat Bcl-2 proteins and 
related family members may directly or indirectly affect the 
permeability of the mitochondria nd thus regulate or either 
destroy cellular homeostasis and death. 
As Bcl-2 (Bcl-XL) is located in the outer mitochondrial 
membrane, it is unlikely that the membrane insertion of Bcl- 
2 can directly lead to the uncoupling of electron transport and 
AhUm disruption. Interaction with the mitochondrial mega- 
channel would have to be based on a two step mechanism, 
which may implicate Bcl-2 insertion into membrane, outer 
membrane pore formation and translocation capability into 
the intermembrane space or inner mitochondrial membrane 
of proteins known to form heterodimers with Bcl-2 (or Bcl- 
2 family members). But this is only speculation. 
Together, these findings suggest he action of Bcl-2 and its 
homologues as direct regulators of the mitochondrial perme- 
ability transition, a hypothesis that would be in accord with 
genetic, functional and structural (crystallographic) data. 
Future investigations will unravel whether apoptosis induc- 
ing Bcl-2 homologues function themselves as mitochondrial 
pores, whether they have to assemble with additional structure 
to form permeability transition pore and their control thereof. 
These findings open new perspectives concerning the cell 
death machinery and its regulatory properties, in which mito- 
chondria make their comeback! 
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